Direct-To-Patient Programs Unveiled As MFN Pricing Deadline Looms

 
• By Alaric DeArment
  
Bristol Myers Squibb and AstraZeneca announced new direct-to-patient sales programs. (Shutterstock)

More from Drug Pricing

More from Scrip